Literature DB >> 27997895

Lower Expression of SPRY4 Predicts a Poor Prognosis and Regulates Cell Proliferation in Colorectal Cancer.

Xiaoling Zhou1, Sheng Xie, Chunluan Yuan, Li Jiang, Xiaoyan Huang, Liumei Li, Yan Chen, Lichuan Luo, Jianxuan Zhang, Daogang Wang, Lijian Liu, Wei Shi, Liang Han, Nong Tang, Yunxi Ji.   

Abstract

BACKGROUND/AIMS: Colorectal cancer (CRC) is the third most common type of cancer worldwide. Sprouty proteins are modulators of mitogeninduced signal transduction processes and therefore can influence the process of cancerogenesis. The encoded protein of Sprouty homolog 4 (SPRY4) is associated with various human cancers. However, its biological role and clinical significance in CRC development and progression are unknown.
METHODS: The aim of this study was to evaluate the expression and biological role of SPRY4 in colorectal cancer. qRT-PCR was performed to investigate the expression of SPRY4 in tumor tissues and corresponding non tumor colorectal tissues from 70 patients. The effect of SPRY4 on proliferation was evaluated by MTT and colony formation assays. CRC cells transfected with SPRY4 were injected into nude mice to study the effect of SPRY4 on tumorigenesis in vivo.
RESULTS: The lower expression of SPRY4 was remarkably correlated with deep tumor invasion and advanced TNM stage. Multivariate analyses revealed that SPRY4 expression served as an independent predictor for overall survival. Using 5-aza treatment, we also observed that SPRY4 expression can be affected by DNA methylation. Further experiments revealed that overexpressed SPRY4 significantly inhibited CRC cell proliferation both in vitro and in vivo.
CONCLUSION: Our study demonstrated that SPRY4 is involved in the development and progression of colorectal cancer by regulating cell proliferation and shows that SPRY4 may be a potential diagnostic and prognostic target in patients with colorectal cancer.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27997895     DOI: 10.1159/000453195

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

Review 1.  The Sprouty/Spred family as tumor suppressors: Coming of age.

Authors:  Tetsuro Kawazoe; Koji Taniguchi
Journal:  Cancer Sci       Date:  2019-04-23       Impact factor: 6.716

2.  A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.

Authors:  Hui-Hui Xu; Hui-Li Wang; Tong-Jin Xing; Xue-Quan Wang
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

3.  Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.

Authors:  Sultana Mehbuba Hossain; Gregory Gimenez; Peter A Stockwell; Peter Tsai; Cristin G Print; Janusz Rys; Bozena Cybulska-Stopa; Magda Ratajska; Agnieszka Harazin-Lechowska; Suzan Almomani; Christopher Jackson; Aniruddha Chatterjee; Michael R Eccles
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

4.  MicroRNA‑181 serves an oncogenic role in breast cancer via the inhibition of SPRY4.

Authors:  Yifu Tian; Xiaodan Fu; Qingling Li; Ying Wang; Dan Fan; Qin Zhou; Weilu Kuang; Liangfang Shen
Journal:  Mol Med Rep       Date:  2018-10-22       Impact factor: 2.952

5.  Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells.

Authors:  Burcu Emine Celik-Selvi; Astrid Stütz; Christoph-Erik Mayer; Jihen Salhi; Gerald Siegwart; Hedwig Sutterlüty
Journal:  Cells       Date:  2019-08-01       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.